451 related articles for article (PubMed ID: 30910851)
21. Cultivated Orostachys japonicus extract inhibits VEGF-induced angiogenesis via regulation of VEGFR2 signaling pathway in vitro and in vivo.
Cho HD; Lee KW; Won YS; Kim JH; Seo KI
J Ethnopharmacol; 2020 Jun; 256():112664. PubMed ID: 32045685
[TBL] [Abstract][Full Text] [Related]
22. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
23. Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
Ceci C; Tentori L; Atzori MG; Lacal PM; Bonanno E; Scimeca M; Cicconi R; Mattei M; de Martino MG; Vespasiani G; Miano R; Graziani G
Nutrients; 2016 Nov; 8(11):. PubMed ID: 27879653
[TBL] [Abstract][Full Text] [Related]
24. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
26. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
27. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
Pang X; Yi T; Yi Z; Cho SG; Qu W; Pinkaew D; Fujise K; Liu M
Cancer Res; 2009 Jan; 69(2):518-25. PubMed ID: 19147565
[TBL] [Abstract][Full Text] [Related]
28. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation.
Mu X; Shi W; Sun L; Li H; Jiang Z; Zhang L
Molecules; 2012 Jun; 17(6):6854-68. PubMed ID: 22669041
[TBL] [Abstract][Full Text] [Related]
29. PAC-1 and its derivative WF-210 Inhibit Angiogenesis by inhibiting VEGF/VEGFR pathway.
Wang F; Wang L; Li Y; Wang N; Wang Y; Cao Q; Gong P; Yang J; Wu C
Eur J Pharmacol; 2018 Feb; 821():29-38. PubMed ID: 29269017
[TBL] [Abstract][Full Text] [Related]
30. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.
Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T
Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811
[TBL] [Abstract][Full Text] [Related]
31. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
32. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
33. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
[TBL] [Abstract][Full Text] [Related]
34. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Saraswati S; Kanaujia PK; Kumar S; Kumar R; Alhaider AA
Mol Cancer; 2013 Jul; 12():82. PubMed ID: 23895055
[TBL] [Abstract][Full Text] [Related]
35. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
Huang SW; Lien JC; Kuo SC; Huang TF
Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
[TBL] [Abstract][Full Text] [Related]
36.
Hwang B; Gho Y; Kim H; Lee S; Hong SA; Lee TJ; Myung SC; Yun SJ; Choi YH; Kim WJ; Moon SK
Integr Cancer Ther; 2022; 21():15347354221114337. PubMed ID: 35912937
[TBL] [Abstract][Full Text] [Related]
37. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.
Zhang L; Ji Q; Liu X; Chen X; Chen Z; Qiu Y; Sun J; Cai J; Zhu H; Li Q
Cancer Sci; 2013 May; 104(5):604-10. PubMed ID: 23363445
[TBL] [Abstract][Full Text] [Related]
38. A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.
Tate CM; Mc Entire J; Pallini R; Vakana E; Wyss L; Blosser W; Ricci-Vitiani L; D'Alessandris QG; Morgante L; Giannetti S; Larocca LM; Todaro M; Benfante A; Colorito ML; Stassi G; De Maria R; Rowlinson S; Stancato L
PLoS One; 2015; 10(4):e0125697. PubMed ID: 25919028
[TBL] [Abstract][Full Text] [Related]
39. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.
Lai L; Liu J; Zhai D; Lin Q; He L; Dong Y; Zhang J; Lu B; Chen Y; Yi Z; Liu M
Br J Pharmacol; 2012 Feb; 165(4b):1084-96. PubMed ID: 21658027
[TBL] [Abstract][Full Text] [Related]
40. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
